FIELD: organic chemistry, chemical technology.
SUBSTANCE: invention relates to a novel method for synthesis of compound of the formula (VII) , formula (VIII) and formula (IX) that effect on 5-HT-receptors of the central nervous system. In compound of the formula (VII) R represents (C1-C3)-alkyl; Y represents fragment chosen from group comprising (C1-C6)-alkoxy-group, (C1-C6)-alkyl; Ar represents 2,3-dihydrobenzodioxin-5-yl. In compound of the formula (VIII) R represents (C1-C3)-alkyl; Ar represents 2,3-dihydrobenzodioxin-5-yl, and * indicated the chiral center. In compound of the formula (IX) R and Ar are given above; Aryl represents (C6-C12)-aromatic group substituted optionally and comprising up to three substitutes chosen independently from group comprising halogen atoms, alkyl, alkoxy-group, alkoxycarbonyl, nitro-, amino-, alkylamino-, dialkylamino-group, halogenalkyl, dihalogenalkyl, trihalogenalkyl, nitrile and amido-substitutes wherein each comprises six carbon atoms, not above.
EFFECT: improved method of synthesis, valuable medicinal properties of compounds.
11 cl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
METHODS FOR PREPARING DERIVATIVES OF PIPERAZINE AND INTERMEDIATE SUBSTANCE | 2003 |
|
RU2314294C2 |
METHOD FOR PREPARING CHIRAL 1,4-DISUBSTITUTED PIPERAZINES | 2003 |
|
RU2315044C2 |
FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2679914C9 |
SULFONYL UREA AND RELATED COMPOUNDS AND USE THEREOF | 2016 |
|
RU2739356C2 |
SULPHONYLUREAS AND RELATED COMPOUNDS AND THEIR USE | 2016 |
|
RU2795512C2 |
AZALACTAM COMPOUNDS AS INHIBITORS OF HPK1 | 2021 |
|
RU2819642C1 |
NOVEL COMPOUNDS POSSESSING ANTI-INFLAMMATORY ACTIVITY AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEREOF | 2001 |
|
RU2288225C2 |
NOVEL COMPOUNDS OF CONDENSED IMIDAZOLE POSSESSING OF CB2 RECEPTOR AGONIST PROPERTY | 2002 |
|
RU2312864C2 |
CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID-DEHYDROGENASE 1 | 2009 |
|
RU2531272C2 |
SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2815814C1 |
Authors
Dates
2008-01-27—Published
2003-03-10—Filed